|Articles|November 1, 2009

Roth IRA restrictions will lift in 2010

Author(s)Joel M. Blau, CFP, Ronald J. Paprocki, JD, CFP, CHBC

Looking for a financial adviser? With this list of the 150 best financial advisers for physicians, there are plenty to choose from.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

October 31st, 2026

Comparing PSMA-PET agents: What urologists should know

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

October 30th, 2026

Belzutifan plus lenvatinib maintains PFS benefit vs cabozantinib in advanced ccRCC

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.

October 30th, 2026

Chad Ritch, MD, on using PSMA-PET to guide treatment decisions

Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.

October 30th, 2026

Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC

Topline results are expected in November 2026 ahead of a planned sBLA submission.

October 30th, 2026

Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026

Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,

October 29th, 2026

ESMO 2026 recap: Notable updates across genitourinary oncology

A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.

October 29th, 2026

LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC

Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.